Carrillo-Espera R, Morales-Victorino N

Language: Spanish
References: 18
Page: 437-439
PDF size: 67.78 Kb.

ABSTRACT

Antineoplasic agent-induced pulmonary toxicity is an important cause of respiratory failure. These novel antineoplastic agents include imatinib mesylate, a protein tyrosine kinase inhibitor that is encoded by the Bcr-Abl gen created by the Philadelphia chromosome abnormality in chronic myeloid leukemia. Pulmonary toxicity of imatinib is directly related to the dose used. The more severe pulmonary manifestations include pleural effusion by water retention and interstitial pneumonitis. We report the first case published in Mexico of imatinib-induced pulmonary toxicity and its management in the intensive care unit of the Medica Sur Clinic Foundation.

REFERENCES

1. Drucker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.

2. Savage DG, Antman KH. Imatinib mesylate: a new targeted oral therapy. N Engl J Med 2002;346:683-693.

3. Ottman OG, Sawyers CL, Drucker B. A phase II study to determine the safety and anti-leukemic effects of STI 571 in adults patients with Philadelphia chromosome positive acute leukemias. Blood 2000;96:828.

4. O´Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. IRIS investigators: imatinib compared with interferon low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.

5. Kantajarin H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti- Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.

6. Isshiki I. Yamaguchi K, Okamoto S. Interstitial pneumonitis during imatinib therapy. Br J Haematol 2004;125:420.

7. Rosado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: case 3. imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003;21:3171-3173.

8. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty seven cases of drug induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-1164.

9. Yokohama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004;18:645-646.

10. Seki N, Ito A, Watanabe K, Shibakuki R, Seto T, Uematsu K, et al. Irreversible imatinib induced pneumonitis following long term imatinib administration. Intern Med 2007;46:1941-1942.

11. Ma CX, Hobday TJ, Jett JR. Imatinib mesylate induced interstitial pneumonitis. Mayo Clin Proc 2003;78:1578-1579.

12. Rajda J, Phatak PD. Reversible drug induced interstitial pneumonitis following imatinib mesylate therapy. Am J Hematol 2005;79: 80-81.

13. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008;133:528-538.

14. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004;71:301-326.

15. Higenbottam T, Kuwano K, Nemery B, Fujita Y. Understanding the mechanisms of drug associated interstitial lung disease. Br J Cancer 2004;91:31-37.

16. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006;17:372-379.

17. Rossi SE, Erasmus JJ, Mc Adams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-1259.

18. Lin JT, Yeh KT, Fang HY, Chang CS. Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate. Leuk Lymphoma 2006;47:1693-1695.